Edap Tms (NASDAQ:EDAP) Director Joshua Levine Purchases 10,000 Shares

Edap Tms S.A. (NASDAQ:EDAP) Director Joshua Levine acquired 10,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $4.22 per share, with a total value of $42,200.00. Following the transaction, the director directly owned 35,000 shares in the company, valued at approximately $147,700. The trade was a 40.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Edap Tms Price Performance

Shares of NASDAQ:EDAP opened at $4.16 on Thursday. Edap Tms S.A. has a one year low of $1.21 and a one year high of $5.05. The stock has a fifty day moving average of $3.70 and a 200-day moving average of $3.42. The company has a market capitalization of $155.92 million, a PE ratio of -5.14 and a beta of -0.10. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34.

Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). Edap Tms had a negative net margin of 41.47% and a negative return on equity of 137.61%. The company had revenue of $20.48 million for the quarter, compared to analyst estimates of $19.46 million. As a group, equities analysts anticipate that Edap Tms S.A. will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Edap Tms

Hedge funds have recently modified their holdings of the stock. Kovack Advisors Inc. acquired a new position in shares of Edap Tms in the fourth quarter worth $53,000. Rock Springs Capital Management LP increased its stake in shares of Edap Tms by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock worth $4,233,000 after acquiring an additional 16,500 shares during the last quarter. Lido Advisors LLC acquired a new position in shares of Edap Tms in the first quarter worth $40,000. SmartHarvest Portfolios LLC acquired a new position in shares of Edap Tms in the first quarter worth $38,000. Finally, Flax Pond Capital LLC acquired a new position in shares of Edap Tms in the fourth quarter worth $2,623,000. 62.74% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. HC Wainwright cut their price objective on Edap Tms from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Wall Street Zen downgraded Edap Tms from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Edap Tms has a consensus rating of “Hold” and a consensus target price of $6.00.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.